Abivax SA Sponsored ADR $ABVX Shares Sold by Catalio Capital Management LP

Catalio Capital Management LP lessened its stake in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 39.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 98,514 shares of the company’s stock after selling 63,627 shares during the period. Abivax comprises about 2.5% of Catalio Capital Management LP’s portfolio, making the stock its 17th largest holding. Catalio Capital Management LP owned 0.12% of Abivax worth $13,285,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. WPG Advisers LLC lifted its position in shares of Abivax by 125.9% during the 4th quarter. WPG Advisers LLC now owns 454 shares of the company’s stock valued at $61,000 after acquiring an additional 253 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Abivax by 661.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock valued at $53,000 after purchasing an additional 344 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after purchasing an additional 369 shares in the last quarter. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Abivax in the fourth quarter valued at $61,000. Finally, Union Bancaire Privee UBP SA purchased a new stake in shares of Abivax in the fourth quarter valued at $67,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

Abivax Trading Up 2.7%

NASDAQ ABVX opened at $100.15 on Thursday. Abivax SA Sponsored ADR has a 1-year low of $5.69 and a 1-year high of $148.83. The company has a market capitalization of $7.99 billion, a PE ratio of -19.22 and a beta of 0.69. The firm’s fifty day simple moving average is $114.81 and its 200-day simple moving average is $118.49.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.23. The company had revenue of $1.56 million during the quarter, compared to analyst estimates of $0.40 million. As a group, analysts predict that Abivax SA Sponsored ADR will post -3.4 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Citigroup restated an “outperform” rating on shares of Abivax in a report on Tuesday, June 2nd. Wall Street Zen upgraded Abivax from a “sell” rating to a “hold” rating in a report on Saturday, May 23rd. Barclays increased their target price on Abivax from $142.00 to $148.00 and gave the company an “overweight” rating in a report on Tuesday, March 24th. Wedbush upgraded Abivax from an “underperform” rating to a “neutral” rating and reduced their target price for the company from $110.00 to $90.00 in a report on Tuesday, June 2nd. Finally, BTIG Research restated a “buy” rating and issued a $150.00 target price on shares of Abivax in a report on Tuesday. Twelve research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $130.08.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.